Pharmacometrics & Pharmacokinetics (PMK)

PI-052 - A MODELING APPROACH TO EXPEDITE THE DEVELOPMENT OF A NEW LONG-ACTING CONTROLLED-RELEASE MULTIPURPOSE FORMULATION CONTAINING MEDROXYPROGESTRONE ACETATE

PI-053 - A PHASE 1 MICROTRACER STUDY EVALUATING THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTS.

PI-054 - A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS

PI-055 - A SEMI-MECHANISTIC PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL OF ABBV-383 CHARACTERIZING THE INTERPLAY BETWEEN SOLUBLE BCMA (SBMCA) AND FREE AND TOTAL PK.

PI-056 - ALTERNATIVE DOSING GUIDELINES TO IMPROVE OUTCOMES IN MULTIDRUG-RESISTANT TUBERCULOSIS.

PI-060 - CHARACTERIZING COLISTIN PHARMACOKINETICS FOLLOWING A LOADING DOSE: FIRST DESCRIPTION IN AN AFRICAN COHORT.

PI-061 - CLOFAZIMINE PHARMACOKINETICS FOR MULTIDRUG-RESISTANT TB: IMPLICATION OF NOVEL COMBINATION REGIMENS.

PI-063 - DISPOSITION OF BEXICASERIN TO ITS MAJOR METABOLITE, N-CARBAMOYL GLUCURONIDE (M20), IS NOT INFLUENCED BY GENETIC POLYMORPHIC METABOLISM

PI-064 - DRUG-DRUG INTERACTIONS BETWEEN ANDROGEN RECEPTOR SIGNALING INHIBITORS AND DIRECT-ACTING ORAL ANTICOAGULANTS IN PATIENTS WITH PROSTATE CANCER: LIMITED AGREEMENT BETWEEN VARIOUS DRUG-DRUG INTERACTION INFORMATION SOURCES

PI-070 - IMPACT OF EAST ASIAN ETHNICITY ON PHARMACOKINETICS OF SOTATERCEPT

PI-072 - LIKELY INHIBITION OF NON-CYP450 PATHWAYS BY BMS-986196 LEADS TO DOUBLING OF EE EXPOSURE.

PI-073 - MECHANISM-BASED PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF ERYTHROFERRONE: OPTIMIZING RECOMBINANT HUMAN ERYTHROPOIETIN DOSING IN CKD-INDUCED ANEMIA

PI-075 - MODEL-BASED META-ANALYSIS OF PLACEBO-RESPONSE FOR MONTHLY MIGRAINE DAYS IN MIGRAINE PREVENTION CLINICAL TRIALS FROM LITERATURE

PI-080 - PHARMACOKINETICS OF NERANDOMILAST IN HEALTHY VOLUNTEERS

PI-082 - POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF ANUMIGILIMAB, A MONOCLONAL ANTIBODY THAT BLOCKS G-CSF BINDING TO THE G-CSF RECEPTOR

PI-085 - POPULATION PHARMACOKINETIC MODEL OF TOTAL AND UNBOUND PAMIPARIB, A PARP INHIBITOR, IN GLIOBLASTOMA PATIENTS

PI-086 - POPULATION PHARMACOKINETIC OF BMS-986365, A DUAL ANDROGEN RECEPTOR (AR) LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

PI-088 - POPULATION PHARMACOKINETICS OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IN REAL WORLD ADULT PATIENTS WITH CYSTIC FIBROSIS

PI-090 - PROTEIN BINDING: STATIC SOLUTIONS TO A DYNAMIC PROBLEM CAN BE MISLEADING IN DRUG DEVELOPMENT AND REGULATORY EVALUATION.

PI-091 - THE DORSAL FOREARM AS A NOVEL TARGET FOR INTRAMUSCULAR INJECTIONS: CLINICAL PHARMACOKINETIC RESULTS.

PI-093 - TRANSLATIONAL PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR NOVEL MRNA-MODALITY SUPPORTING ENZYME REPLACEMENT THERAPY.

PT-014 - UTILIZING A DISEASE PROGRESSION MODEL TO DEVELOP A CLINICAL TRIAL SIMULATION TOOL THAT OPTIMIZES TRIAL DESIGN FOR AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE.

PII-053 - A NOVEL MODELING APPROACH FOR PREDICTING THE TIME COURSE OF ANTI-DRUG ANTIBODIES OF BIOLOGICS: APPLICATION TO AXATILIMAB AS AN EXAMPLE

PII-056 - ADME PROFILING OF TARGETED ORAL PEPTIDE JNJ-77242113

PII-060 - CHALLENGES IN PREDICTING PEDIATRIC DRUG EXPOSURE WITH ALLOMETRIC SCALING: IMPLICATIONS FOR OPTIMIZING PEDIATRIC TRIAL DESIGNS

PII-062 - COMPREHENSIVE PHARMACOKINETIC ANALYSIS OF ISONIAZID IN A LARGE COHORT OF TUBERCULOSIS PATIENTS: ADVANCED MODELING INCORPORATING EXTENSIVE CLINICAL COVARIATES.

PII-063 - COST EFFECTIVENESS OF INDIVIDUALIZED DOSING FOR A HYPOTHETICAL NEW DRUG IN ATOPIC DERMATITIS: A PHARMACOMETRIC-PHARMACOECONOMIC SIMULATION STUDY.

PII-065 - DRUG-DRUG INTERACTIONS BETWEEN LETERMOVIR AND TARGETED THERAPIES FOR GRAFT VERSUS HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: HOW DO DRUG-DRUG INTERACTION CHECKERS COMPARE?

PII-071 - INTEGRATED MODEL BASED ANALYSES OF MILVEXIAN PHASE 2 SSP TRIAL DATA SUPPORTS PHASE 3 DOSE SELECTION

PII-072 - LEVERAGING SUPERVISED MACHINE LEARNING TO IDENTIFY PREDICTORS OF ADVERSE EVENTS WITH STIMULANT TREATMENT FROM REAL-WORLD DATA

PII-073 - MASS BALANCE, METABOLISM, AND EXCRETION OF [14C] BEXICASERIN IN A SINGLE DOSE RADIOLABEL STUDY IN HEALTHY ADULT MALES.

PII-074 - MODEL INFORMED DOSE OPTIMIZATION OF BALSTILIMAB TO SUPPORT FIXED DOSING ALONE AND IN COMBINATION WITH BOTENSILIMAB IN PATIENTS WITH SOLID TUMORS.

PII-076 - MODEL-ESTIMATED TISSUE PHARMACOLOGY AS A SURROGATE OF MONOCLONAL ANTIBODY CLINICAL EFFICACY DOSE RESPONSE: CASE STUDY USING DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS.

PII-077 - PHARMACODYNAMIC MODEL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER RECEIVING PACLITAXEL

PII-078 - PHARMACOKINETIC BRIDGING OF JNJ-77242113 ORAL SOLUTION AND TABLET FORMULATIONS.

PII-080 - PHARMACOKINETICS OF A FULLY HUMAN BISPECIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CLUSTER OF DIFFERENTIATION (CD3) BINDING MONOCLONAL ANTIBODY (AMG 340) IN SUBJECTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER

PII-087 - POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DONIDALORSEN, AN ANTISENSE OLIGONUCLEOTIDE IN DEVELOPMENT FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA.

PII-089 - POPULATION PHARMACOKINETICS OF ORAL MELTDOSE TACROLIMUS (LCPT) IN DE NOVO KIDNEY TRANSPLANT PATIENTS.

PII-090 - POPULATION PK (POPPK) AND EXPOSURE-SAFETY (E-S) ANALYSIS OF BT5528, A BICYCLE TOXIN CONJUGATE (BTC®), IN PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH EPHA2 EXPRESSION.

PII-092 - THE EFFECT OF POLYDRUG USE AND FENTANYL VACCINE ON THE PHARMACOKINETICS OF FENTANYL

PII-093 - TRANSLATIONAL MODELING OF BTZ-043 IN PREDICTING PHASE IIA EFFICACY AND EVALUATION OF DRUG-DRUG INTERACTIONS WITH BPAL IN MURINE MODELS

PII-094 - UNRAVELING MOXIFLOXACIN'S BEHAVIOR IN NEXT-GENERATION TB REGIMENS.

LB-014 - POPULATION PHARMACOKINETICS AND BIOAVAILABILITY OF TACROLIMUS ORAL SUSPENSION IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)